This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-29b-3p | ABL1 | 0.02 | 0.91431 | -0.21 | 0.07804 | miRNATAP | -0.24 | 0 | NA | |
2 | hsa-miR-29b-3p | ABL2 | 0.02 | 0.91431 | 0.82 | 0 | mirMAP | -0.16 | 0 | NA | |
3 | hsa-miR-29b-3p | ABLIM2 | 0.02 | 0.91431 | 0.29 | 0.2377 | mirMAP | -0.27 | 0.00018 | NA | |
4 | hsa-miR-29b-3p | ACVR2A | 0.02 | 0.91431 | -0.41 | 0.00039 | miRNATAP | -0.11 | 0.00111 | NA | |
5 | hsa-miR-29b-3p | ADAM11 | 0.02 | 0.91431 | -0.37 | 0.13471 | mirMAP | -0.42 | 0 | NA | |
6 | hsa-miR-29b-3p | ADAM19 | 0.02 | 0.91431 | 0.19 | 0.3039 | MirTarget; miRNATAP | -0.15 | 0.00528 | NA | |
7 | hsa-miR-29b-3p | ADAM22 | 0.02 | 0.91431 | 0.64 | 0.00696 | miRNATAP | -0.32 | 0 | NA | |
8 | hsa-miR-29b-3p | ADAMTS10 | 0.02 | 0.91431 | 0.32 | 0.12111 | MirTarget; miRNATAP | -0.32 | 0 | NA | |
9 | hsa-miR-29b-3p | ADAMTS18 | 0.02 | 0.91431 | 3.26 | 0 | miRNATAP | -0.29 | 0.01017 | NA | |
10 | hsa-miR-29b-3p | ADAMTS19 | 0.02 | 0.91431 | -1.3 | 0.01069 | miRNATAP | -0.76 | 0 | NA | |
11 | hsa-miR-29b-3p | ADAMTS6 | 0.02 | 0.91431 | 1.2 | 0 | MirTarget; miRNATAP | -0.3 | 0 | NA | |
12 | hsa-miR-29b-3p | ADAMTS9 | 0.02 | 0.91431 | 0.8 | 3.0E-5 | miRNATAP | -0.29 | 0 | NA | |
13 | hsa-miR-29b-3p | ADARB1 | 0.02 | 0.91431 | -0.34 | 0.06631 | mirMAP | -0.36 | 0 | NA | |
14 | hsa-miR-29b-3p | ADCY1 | 0.02 | 0.91431 | 0.36 | 0.16982 | mirMAP | -0.29 | 0.00014 | NA | |
15 | hsa-miR-29b-3p | ADCYAP1R1 | 0.02 | 0.91431 | -3.17 | 0 | miRNATAP | -0.9 | 0 | NA | |
16 | hsa-miR-29b-3p | AFF4 | 0.02 | 0.91431 | -0.27 | 0.01565 | miRNATAP | -0.15 | 0 | NA | |
17 | hsa-miR-29b-3p | AGPAT4 | 0.02 | 0.91431 | 0.09 | 0.61321 | MirTarget; miRNATAP | -0.35 | 0 | NA | |
18 | hsa-miR-29b-3p | AHNAK | 0.02 | 0.91431 | -1.21 | 0 | MirTarget | -0.3 | 0 | NA | |
19 | hsa-miR-29b-3p | AKT3 | 0.02 | 0.91431 | -0.27 | 0.18865 | miRNATAP | -0.51 | 0 | 26512921 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
20 | hsa-miR-29b-3p | ANK3 | 0.02 | 0.91431 | -0.55 | 0.00086 | miRNATAP | -0.11 | 0.02889 | NA | |
21 | hsa-miR-29b-3p | ANKRD13B | 0.02 | 0.91431 | 1.41 | 0 | MirTarget; miRNATAP | -0.13 | 0.02422 | NA | |
22 | hsa-miR-29b-3p | ANTXR2 | 0.02 | 0.91431 | -0.73 | 0.00186 | miRNATAP | -0.35 | 0 | NA | |
23 | hsa-miR-29b-3p | AP4E1 | 0.02 | 0.91431 | 0.05 | 0.63665 | miRNATAP | -0.1 | 0.00064 | NA | |
24 | hsa-miR-29b-3p | APPBP2 | 0.02 | 0.91431 | -0.15 | 0.05098 | miRNATAP | -0.14 | 0 | NA | |
25 | hsa-miR-29b-3p | ARPP19 | 0.02 | 0.91431 | 0.11 | 0.27444 | MirTarget; miRNATAP | -0.13 | 0 | NA | |
26 | hsa-miR-29b-3p | ARRDC3 | 0.02 | 0.91431 | -0.15 | 0.28741 | MirTarget; miRNATAP | -0.25 | 0 | NA | |
27 | hsa-miR-29b-3p | ARRDC4 | 0.02 | 0.91431 | -1.01 | 0 | miRNATAP | -0.19 | 0.00021 | NA | |
28 | hsa-miR-29b-3p | ARVCF | 0.02 | 0.91431 | 0.32 | 0.05547 | MirTarget; miRNATAP | -0.27 | 0 | NA | |
29 | hsa-miR-29b-3p | ASB1 | 0.02 | 0.91431 | -0.28 | 0.00868 | mirMAP | -0.18 | 0 | NA | |
30 | hsa-miR-29b-3p | ASIC1 | 0.02 | 0.91431 | -0.41 | 0.13205 | miRNATAP | -0.29 | 0.00027 | NA | |
31 | hsa-miR-29b-3p | ATP2B2 | 0.02 | 0.91431 | -1.89 | 0 | miRNATAP | -0.8 | 0 | NA | |
32 | hsa-miR-29b-3p | ATP2B4 | 0.02 | 0.91431 | -0.64 | 0.00597 | MirTarget; miRNATAP | -0.54 | 0 | NA | |
33 | hsa-miR-29b-3p | ATXN1 | 0.02 | 0.91431 | -0.51 | 0.00026 | miRNATAP | -0.24 | 0 | NA | |
34 | hsa-miR-29b-3p | ATXN1L | 0.02 | 0.91431 | -0.07 | 0.43241 | miRNATAP | -0.11 | 2.0E-5 | NA | |
35 | hsa-miR-29b-3p | B4GALT6 | 0.02 | 0.91431 | 0.03 | 0.90707 | MirTarget | -0.2 | 0.00156 | NA | |
36 | hsa-miR-29b-3p | BACE1 | 0.02 | 0.91431 | -0.1 | 0.49755 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.39 | 0 | NA | |
37 | hsa-miR-29b-3p | BACH2 | 0.02 | 0.91431 | -0.15 | 0.55909 | MirTarget; miRNATAP | -0.25 | 0.00143 | NA | |
38 | hsa-miR-29b-3p | BCL2 | 0.02 | 0.91431 | -0.9 | 0 | miRNAWalker2 validate; miRTarBase | -0.2 | 0.00052 | 20041405 | Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29 |
39 | hsa-miR-29b-3p | BCORL1 | 0.02 | 0.91431 | 0.35 | 0.01214 | miRNATAP | -0.16 | 9.0E-5 | NA | |
40 | hsa-miR-29b-3p | BLMH | 0.02 | 0.91431 | 0.29 | 0.01725 | MirTarget; miRNATAP | -0.11 | 0.00183 | NA | |
41 | hsa-miR-29b-3p | BRD3 | 0.02 | 0.91431 | 0.37 | 0.00013 | miRNATAP | -0.19 | 0 | NA | |
42 | hsa-miR-29b-3p | BTBD7 | 0.02 | 0.91431 | -0.17 | 0.03473 | miRNATAP | -0.1 | 1.0E-5 | NA | |
43 | hsa-miR-29b-3p | BTG2 | 0.02 | 0.91431 | -1.76 | 0 | miRNATAP | -0.17 | 0.00983 | NA | |
44 | hsa-miR-29b-3p | C17orf51 | 0.02 | 0.91431 | -0.24 | 0.16845 | mirMAP | -0.2 | 7.0E-5 | NA | |
45 | hsa-miR-29b-3p | C1orf21 | 0.02 | 0.91431 | -0.73 | 9.0E-5 | miRNATAP | -0.3 | 0 | NA | |
46 | hsa-miR-29b-3p | C2CD4C | 0.02 | 0.91431 | 0.08 | 0.77156 | mirMAP | -0.27 | 0.00063 | NA | |
47 | hsa-miR-29b-3p | C5orf24 | 0.02 | 0.91431 | 0.08 | 0.41066 | miRNATAP | -0.18 | 0 | NA | |
48 | hsa-miR-29b-3p | CACNA1C | 0.02 | 0.91431 | -0.18 | 0.557 | MirTarget | -0.7 | 0 | NA | |
49 | hsa-miR-29b-3p | CACNG4 | 0.02 | 0.91431 | -0.7 | 0.19815 | miRNATAP | -0.76 | 0 | NA | |
50 | hsa-miR-29b-3p | CALU | 0.02 | 0.91431 | 0.67 | 0 | miRNAWalker2 validate; MirTarget | -0.15 | 0 | NA | |
51 | hsa-miR-29b-3p | CAMK1D | 0.02 | 0.91431 | -0.71 | 0.00255 | miRNATAP | -0.37 | 0 | NA | |
52 | hsa-miR-29b-3p | CAMK2B | 0.02 | 0.91431 | -2.34 | 0 | mirMAP | -0.44 | 0.00028 | NA | |
53 | hsa-miR-29b-3p | CAMK2G | 0.02 | 0.91431 | -0.53 | 0.00041 | miRNATAP | -0.27 | 0 | NA | |
54 | hsa-miR-29b-3p | CAPN6 | 0.02 | 0.91431 | -1.29 | 0.02537 | miRNATAP | -0.6 | 0.00041 | NA | |
55 | hsa-miR-29b-3p | CAPN7 | 0.02 | 0.91431 | -0.14 | 0.11991 | miRNATAP | -0.13 | 0 | NA | |
56 | hsa-miR-29b-3p | CAV2 | 0.02 | 0.91431 | -0.27 | 0.24247 | MirTarget; miRNATAP | -0.33 | 0 | NA | |
57 | hsa-miR-29b-3p | CBFA2T2 | 0.02 | 0.91431 | 0.38 | 0.00165 | mirMAP | -0.19 | 0 | NA | |
58 | hsa-miR-29b-3p | CBL | 0.02 | 0.91431 | 0.29 | 0.01267 | mirMAP | -0.14 | 3.0E-5 | NA | |
59 | hsa-miR-29b-3p | CBX1 | 0.02 | 0.91431 | 0.33 | 0.00082 | miRNATAP | -0.16 | 0 | NA | |
60 | hsa-miR-29b-3p | CBX5 | 0.02 | 0.91431 | 0.16 | 0.24446 | miRNATAP | -0.17 | 4.0E-5 | NA | |
61 | hsa-miR-29b-3p | CBX6 | 0.02 | 0.91431 | -0.52 | 0.03506 | miRNATAP | -0.53 | 0 | NA | |
62 | hsa-miR-29b-3p | CCND2 | 0.02 | 0.91431 | -0.27 | 0.3112 | MirTarget; miRNATAP | -0.21 | 0.00653 | 24130168; 22330340 | We further demonstrated that miR-29 family acted as tumor suppressors through targeting CCND2 and matrix metalloproteinase-2 genes in GC;In addition to CCND2 miR-29 also targets E2F7 another cell cycle regulator |
63 | hsa-miR-29b-3p | CD93 | 0.02 | 0.91431 | 0.56 | 0.00095 | MirTarget | -0.23 | 0 | NA | |
64 | hsa-miR-29b-3p | CD99L2 | 0.02 | 0.91431 | -0.29 | 0.07048 | mirMAP | -0.25 | 0 | NA | |
65 | hsa-miR-29b-3p | CDC42BPA | 0.02 | 0.91431 | -0.05 | 0.73917 | MirTarget; miRNATAP | -0.18 | 7.0E-5 | NA | |
66 | hsa-miR-29b-3p | CECR2 | 0.02 | 0.91431 | -0.99 | 0.00379 | miRNAWalker2 validate | -0.43 | 2.0E-5 | NA | |
67 | hsa-miR-29b-3p | CEP68 | 0.02 | 0.91431 | -0.36 | 0.00246 | MirTarget | -0.24 | 0 | NA | |
68 | hsa-miR-29b-3p | CFL2 | 0.02 | 0.91431 | -1.3 | 0 | miRNATAP | -0.61 | 0 | NA | |
69 | hsa-miR-29b-3p | CHD5 | 0.02 | 0.91431 | -0.92 | 0.01521 | mirMAP | -0.87 | 0 | NA | |
70 | hsa-miR-29b-3p | CHSY1 | 0.02 | 0.91431 | 0.46 | 1.0E-5 | MirTarget; miRNATAP | -0.13 | 1.0E-5 | NA | |
71 | hsa-miR-29b-3p | CILP2 | 0.02 | 0.91431 | 3.02 | 0 | MirTarget; miRNATAP | -0.46 | 0.0003 | NA | |
72 | hsa-miR-29b-3p | CLCN6 | 0.02 | 0.91431 | -0.03 | 0.77926 | mirMAP | -0.18 | 0 | NA | |
73 | hsa-miR-29b-3p | CLDN19 | 0.02 | 0.91431 | -0.04 | 0.93631 | mirMAP | -0.37 | 0.00737 | NA | |
74 | hsa-miR-29b-3p | CLEC2L | 0.02 | 0.91431 | 0.44 | 0.37541 | MirTarget; miRNATAP | -0.74 | 0 | NA | |
75 | hsa-miR-29b-3p | CNTN5 | 0.02 | 0.91431 | -0.22 | 0.61957 | miRNATAP | -0.55 | 2.0E-5 | NA | |
76 | hsa-miR-29b-3p | COL15A1 | 0.02 | 0.91431 | 0.68 | 0.00158 | MirTarget; miRNATAP | -0.27 | 2.0E-5 | NA | |
77 | hsa-miR-29b-3p | COL16A1 | 0.02 | 0.91431 | 0.59 | 0.00556 | miRNATAP | -0.39 | 0 | NA | |
78 | hsa-miR-29b-3p | COL1A2 | 0.02 | 0.91431 | 1.99 | 0 | miRNATAP | -0.26 | 0.00065 | NA | |
79 | hsa-miR-29b-3p | COL3A1 | 0.02 | 0.91431 | 2.03 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.3 | 0.00014 | NA | |
80 | hsa-miR-29b-3p | COL4A1 | 0.02 | 0.91431 | 1.79 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.32 | 0 | NA | |
81 | hsa-let-7g-5p | COL4A2 | 0.3 | 0.02968 | 1.02 | 0 | miRNATAP | -0.49 | 0 | NA | |
82 | hsa-miR-1266-5p | COL4A2 | 0.98 | 0.00203 | 1.02 | 0 | MirTarget | -0.21 | 0 | NA | |
83 | hsa-miR-155-5p | COL4A2 | 0.71 | 0.00687 | 1.02 | 0 | miRNAWalker2 validate | -0.2 | 1.0E-5 | NA | |
84 | hsa-miR-16-5p | COL4A2 | 0.47 | 0.02635 | 1.02 | 0 | miRNAWalker2 validate | -0.28 | 0 | NA | |
85 | hsa-miR-26b-5p | COL4A2 | -0.5 | 0.01181 | 1.02 | 0 | miRNAWalker2 validate | -0.31 | 0 | NA | |
86 | hsa-miR-29a-3p | COL4A2 | -0.24 | 0.13853 | 1.02 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.41 | 0 | NA | |
87 | hsa-miR-29b-3p | COL4A2 | 0.02 | 0.91431 | 1.02 | 0 | miRTarBase; MirTarget; miRNATAP | -0.37 | 0 | NA | |
88 | hsa-miR-29c-3p | COL4A2 | -1.34 | 0 | 1.02 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.32 | 0 | NA | |
89 | hsa-miR-92a-3p | COL4A2 | 1.06 | 0 | 1.02 | 0 | miRNAWalker2 validate | -0.24 | 7.0E-5 | NA | |
90 | hsa-miR-29b-3p | COL4A3 | 0.02 | 0.91431 | -0.75 | 0.03615 | MirTarget; miRNATAP | -0.34 | 0.00126 | NA | |
91 | hsa-miR-29b-3p | COL4A4 | 0.02 | 0.91431 | 0.2 | 0.56272 | MirTarget; miRNATAP | -0.36 | 0.00048 | NA | |
92 | hsa-miR-29b-3p | COL4A5 | 0.02 | 0.91431 | -2.08 | 0 | miRNATAP | -0.64 | 0 | NA | |
93 | hsa-miR-29b-3p | COL4A6 | 0.02 | 0.91431 | -3.18 | 0 | miRNATAP | -0.73 | 0 | NA | |
94 | hsa-miR-29b-3p | COL5A1 | 0.02 | 0.91431 | 1.68 | 0 | MirTarget; miRNATAP | -0.26 | 0.00033 | NA | |
95 | hsa-miR-29b-3p | COL5A2 | 0.02 | 0.91431 | 1.97 | 0 | MirTarget; miRNATAP | -0.24 | 0.00035 | NA | |
96 | hsa-miR-29b-3p | COL6A3 | 0.02 | 0.91431 | 1.53 | 0 | MirTarget; miRNATAP | -0.38 | 0 | NA | |
97 | hsa-miR-29b-3p | CORO6 | 0.02 | 0.91431 | -0.93 | 0.00193 | miRNATAP | -0.64 | 0 | NA | |
98 | hsa-miR-29b-3p | CPEB3 | 0.02 | 0.91431 | -0.73 | 0 | MirTarget; miRNATAP | -0.1 | 0.0033 | NA | |
99 | hsa-miR-29b-3p | CPLX2 | 0.02 | 0.91431 | -2.78 | 0 | mirMAP | -0.57 | 0.00099 | NA | |
100 | hsa-miR-29b-3p | CPNE8 | 0.02 | 0.91431 | 0.01 | 0.9743 | miRNATAP | -0.33 | 0 | NA | |
101 | hsa-miR-29b-3p | CREB5 | 0.02 | 0.91431 | 0.01 | 0.953 | MirTarget; miRNATAP | -0.39 | 0 | NA | |
102 | hsa-miR-29b-3p | CRISPLD1 | 0.02 | 0.91431 | 1.34 | 1.0E-5 | MirTarget; miRNATAP | -0.75 | 0 | NA | |
103 | hsa-miR-29b-3p | CSGALNACT2 | 0.02 | 0.91431 | 0.61 | 0 | miRNATAP | -0.24 | 0 | NA | |
104 | hsa-miR-29b-3p | CSRNP2 | 0.02 | 0.91431 | 0.24 | 0.00293 | miRNATAP | -0.14 | 0 | NA | |
105 | hsa-miR-29b-3p | CTDSPL2 | 0.02 | 0.91431 | 0.34 | 0.00044 | MirTarget | -0.13 | 0 | NA | |
106 | hsa-miR-29b-3p | CYBRD1 | 0.02 | 0.91431 | -1.57 | 0 | MirTarget | -0.38 | 0 | NA | |
107 | hsa-miR-29b-3p | DAAM1 | 0.02 | 0.91431 | -0.34 | 0.0105 | MirTarget; miRNATAP | -0.25 | 0 | NA | |
108 | hsa-miR-29b-3p | DBT | 0.02 | 0.91431 | -0.4 | 0.0001 | MirTarget | -0.12 | 8.0E-5 | NA | |
109 | hsa-miR-29b-3p | DCAF5 | 0.02 | 0.91431 | -0.43 | 0 | miRNATAP | -0.11 | 0 | NA | |
110 | hsa-miR-29b-3p | DCUN1D4 | 0.02 | 0.91431 | -0.26 | 0.02159 | MirTarget; miRNATAP | -0.15 | 0 | NA | |
111 | hsa-miR-29b-3p | DCX | 0.02 | 0.91431 | -0.84 | 0.10669 | MirTarget; miRNATAP | -0.85 | 0 | NA | |
112 | hsa-miR-29b-3p | DDX3Y | 0.02 | 0.91431 | -1.08 | 0.26927 | miRNATAP | -0.71 | 0.01412 | NA | |
113 | hsa-miR-29b-3p | DDX6 | 0.02 | 0.91431 | 0.09 | 0.36428 | miRNATAP | -0.15 | 0 | NA | |
114 | hsa-miR-29b-3p | DGKH | 0.02 | 0.91431 | 0.67 | 5.0E-5 | miRNATAP | -0.3 | 0 | NA | |
115 | hsa-miR-29b-3p | DIO2 | 0.02 | 0.91431 | 1.13 | 1.0E-5 | miRNATAP | -0.41 | 0 | NA | |
116 | hsa-miR-29b-3p | DIP2C | 0.02 | 0.91431 | -0.44 | 0.01713 | MirTarget; miRNATAP | -0.42 | 0 | NA | |
117 | hsa-miR-29b-3p | DIRAS1 | 0.02 | 0.91431 | -2.52 | 0 | mirMAP | -0.49 | 7.0E-5 | NA | |
118 | hsa-miR-29b-3p | DLG2 | 0.02 | 0.91431 | -1.81 | 0 | MirTarget; miRNATAP | -0.87 | 0 | NA | |
119 | hsa-miR-29b-3p | DLGAP1 | 0.02 | 0.91431 | -0.65 | 0.09462 | miRNATAP | -0.44 | 0.00011 | NA | |
120 | hsa-miR-29b-3p | DNMT3A | 0.02 | 0.91431 | 0.3 | 0.0262 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.2 | 0 | 25874772; 23939044; 26171207; 24798303; 26471361; 17890317; 22479643; 25746661 | The de-regulation of the miR-29 family and DNA methyltransferase 3A DNMT3A is associated with gastric cancer GC;The miR-29 family miR-29a -29b and -29c which negatively regulates DNMT3A and DNMT3B was examined in association with the Wnt/β-catenin signaling pathway; The expression of miR-29a and miR-29b was partially regulated by DNMT3A and DNMT3B in a positive feedback loop;In addition a significant inverse correlation was identified between the expression levels of DNMT3A and miR-29b in estrogen receptor-positive breast cancer patients P=0.027;Consistent with miR-29's role in targeting DNA methyltransferase 3A DNMT3A a key enzyme regulating DNA methylation we found a significant inverse correlation P<0.001 between miR-29 and DNMT3A gene expression suggesting that they might be functionally antagonistic;Mechanistically ATDC exerted its oncogenic effects by suppressing miR-29 and subsequent upregulation of DNMT3A leading to DNA methylation and silencing of the tumor suppressor PTEN;Among the reported down-regulated miRNAs in lung cancer the miRNA miR-29 family 29a 29b and 29c has intriguing complementarities to the 3'-UTRs of DNA methyltransferase DNMT3A and -3B de novo methyltransferases two key enzymes involved in DNA methylation that are frequently up-regulated in lung cancer and associated with poor prognosis;The miR-29 family and predicted target genes were among the most strongly anti-correlated miRNA:mRNA pairs; over-expression of miR-29a in vitro repressed several anti-correlated genes including DNMT3A and DNMT3B and substantially decreased ovarian cancer cell viability;DNMT3A and 3B genes can be regulated post-transcriptionally by miR-29 family |
121 | hsa-miR-29b-3p | DPYSL2 | 0.02 | 0.91431 | 0.6 | 0.0002 | miRNATAP | -0.25 | 0 | NA | |
122 | hsa-miR-29b-3p | DPYSL3 | 0.02 | 0.91431 | -0.04 | 0.90157 | MirTarget | -0.78 | 0 | NA | |
123 | hsa-miR-29b-3p | DPYSL5 | 0.02 | 0.91431 | 0.21 | 0.71777 | MirTarget; miRNATAP | -1.26 | 0 | NA | |
124 | hsa-miR-29b-3p | DRD1 | 0.02 | 0.91431 | 0.23 | 0.64754 | miRNATAP | -0.29 | 0.04991 | NA | |
125 | hsa-miR-29b-3p | DRP2 | 0.02 | 0.91431 | 0.22 | 0.49257 | miRNATAP | -0.66 | 0 | NA | |
126 | hsa-miR-29b-3p | ECE1 | 0.02 | 0.91431 | 0.12 | 0.25007 | mirMAP | -0.1 | 0.00112 | NA | |
127 | hsa-miR-29b-3p | EHD2 | 0.02 | 0.91431 | -0.36 | 0.08303 | miRNATAP | -0.37 | 0 | NA | |
128 | hsa-miR-29b-3p | ELF2 | 0.02 | 0.91431 | 0.09 | 0.2369 | MirTarget; miRNATAP | -0.15 | 0 | NA | |
129 | hsa-miR-29b-3p | ELL2 | 0.02 | 0.91431 | -1.46 | 0 | miRNATAP | -0.13 | 0.01145 | NA | |
130 | hsa-miR-29b-3p | ELMO2 | 0.02 | 0.91431 | 0.07 | 0.42477 | miRNATAP | -0.15 | 0 | NA | |
131 | hsa-miR-29b-3p | ELN | 0.02 | 0.91431 | 0.45 | 0.13752 | MirTarget; miRNATAP | -0.61 | 0 | NA | |
132 | hsa-miR-29b-3p | ELOVL4 | 0.02 | 0.91431 | -1.2 | 2.0E-5 | miRNATAP | -0.69 | 0 | NA | |
133 | hsa-miR-29b-3p | ENTPD1 | 0.02 | 0.91431 | 0.24 | 0.0602 | mirMAP | -0.24 | 0 | NA | |
134 | hsa-miR-29b-3p | EPHA3 | 0.02 | 0.91431 | 0.18 | 0.53588 | miRNATAP | -0.65 | 0 | NA | |
135 | hsa-miR-29b-3p | EPHA8 | 0.02 | 0.91431 | -0.71 | 0.12507 | mirMAP | -0.32 | 0.01905 | NA | |
136 | hsa-miR-29b-3p | ERC1 | 0.02 | 0.91431 | -0.11 | 0.38794 | miRNATAP | -0.19 | 0 | NA | |
137 | hsa-miR-29b-3p | ESR1 | 0.02 | 0.91431 | -1.04 | 3.0E-5 | miRNAWalker2 validate; miRTarBase | -0.19 | 0.0088 | 25622979 | In the present study we show that S100A7 significantly upregulates the expression of miR-29b in Estrogen Receptor ER-positive breast cancer cells represented by MCF7 and significantly downregulates miR-29b in ER-negative cells represented by MDA-MB-231 Corrected |
138 | hsa-miR-29b-3p | FAM168B | 0.02 | 0.91431 | -0.14 | 0.19372 | MirTarget | -0.23 | 0 | NA | |
139 | hsa-miR-29b-3p | FBN1 | 0.02 | 0.91431 | 0.69 | 0.00279 | miRNATAP | -0.42 | 0 | NA | |
140 | hsa-miR-29b-3p | FEM1B | 0.02 | 0.91431 | -0.19 | 0.08171 | miRNATAP | -0.26 | 0 | NA | |
141 | hsa-miR-29b-3p | FERMT2 | 0.02 | 0.91431 | -0.9 | 0.00065 | MirTarget; miRNATAP | -0.68 | 0 | NA | |
142 | hsa-miR-29b-3p | FKRP | 0.02 | 0.91431 | -0.04 | 0.66297 | mirMAP | -0.13 | 0 | NA | |
143 | hsa-miR-29b-3p | FOXK1 | 0.02 | 0.91431 | 0.73 | 0 | mirMAP | -0.16 | 0.00011 | NA | |
144 | hsa-miR-29b-3p | FOXO3 | 0.02 | 0.91431 | -0.04 | 0.72028 | miRNATAP | -0.15 | 0 | NA | |
145 | hsa-miR-29b-3p | FOXO4 | 0.02 | 0.91431 | -0.52 | 2.0E-5 | miRNATAP | -0.11 | 0.00308 | NA | |
146 | hsa-miR-29b-3p | FRAS1 | 0.02 | 0.91431 | 0.69 | 0.06741 | miRNATAP | -0.43 | 9.0E-5 | NA | |
147 | hsa-miR-29b-3p | FREM1 | 0.02 | 0.91431 | -0.82 | 0.06787 | MirTarget; miRNATAP | -0.7 | 0 | NA | |
148 | hsa-miR-29b-3p | FREM2 | 0.02 | 0.91431 | -0.44 | 0.46353 | MirTarget | -0.7 | 6.0E-5 | NA | |
149 | hsa-miR-29b-3p | FRMD4A | 0.02 | 0.91431 | -0.2 | 0.1546 | miRNATAP | -0.26 | 0 | NA | |
150 | hsa-miR-29b-3p | FZD1 | 0.02 | 0.91431 | 0.08 | 0.61656 | mirMAP | -0.25 | 0 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | NEUROGENESIS | 77 | 1402 | 1.155e-13 | 5.376e-10 |
2 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 82 | 1672 | 6.517e-12 | 1.516e-08 |
3 | EXTRACELLULAR STRUCTURE ORGANIZATION | 29 | 304 | 4.98e-11 | 7.725e-08 |
4 | MULTICELLULAR ORGANISMAL MACROMOLECULE METABOLIC PROCESS | 14 | 79 | 1.98e-09 | 1.368e-06 |
5 | MULTICELLULAR ORGANISM METABOLIC PROCESS | 15 | 93 | 2.052e-09 | 1.368e-06 |
6 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 54 | 1008 | 2.059e-09 | 1.368e-06 |
7 | CELL DEVELOPMENT | 68 | 1426 | 1.82e-09 | 1.368e-06 |
8 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 49 | 872 | 2.637e-09 | 1.534e-06 |
9 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 44 | 750 | 5.054e-09 | 2.138e-06 |
10 | REGULATION OF CELL DIFFERENTIATION | 69 | 1492 | 4.802e-09 | 2.138e-06 |
11 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 78 | 1784 | 4.96e-09 | 2.138e-06 |
12 | REGULATION OF CELL DEVELOPMENT | 47 | 836 | 5.633e-09 | 2.184e-06 |
13 | NEURON PROJECTION DEVELOPMENT | 36 | 545 | 6.704e-09 | 2.4e-06 |
14 | HEAD DEVELOPMENT | 42 | 709 | 8.734e-09 | 2.64e-06 |
15 | NEURON DIFFERENTIATION | 48 | 874 | 8.055e-09 | 2.64e-06 |
16 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 57 | 1142 | 9.078e-09 | 2.64e-06 |
17 | RESPONSE TO ENDOGENOUS STIMULUS | 66 | 1450 | 2.026e-08 | 5.087e-06 |
18 | CELLULAR COMPONENT MORPHOGENESIS | 48 | 900 | 2.017e-08 | 5.087e-06 |
19 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 44 | 788 | 2.186e-08 | 5.087e-06 |
20 | CIRCULATORY SYSTEM DEVELOPMENT | 44 | 788 | 2.186e-08 | 5.087e-06 |
21 | NEURON DEVELOPMENT | 40 | 687 | 3.228e-08 | 7.153e-06 |
22 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 33 | 513 | 5.482e-08 | 1.159e-05 |
23 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 63 | 1395 | 5.938e-08 | 1.201e-05 |
24 | HEART DEVELOPMENT | 31 | 466 | 6.63e-08 | 1.242e-05 |
25 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 27 | 368 | 6.674e-08 | 1.242e-05 |
26 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 43 | 801 | 9.685e-08 | 1.733e-05 |
27 | POSITIVE REGULATION OF NEURON DIFFERENTIATION | 24 | 306 | 1.056e-07 | 1.76e-05 |
28 | REGULATION OF NEURON DIFFERENTIATION | 34 | 554 | 1.059e-07 | 1.76e-05 |
29 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 49 | 983 | 1.15e-07 | 1.846e-05 |
30 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 28 | 408 | 1.536e-07 | 2.383e-05 |
31 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 42 | 799 | 2.43e-07 | 3.647e-05 |
32 | POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 20 | 232 | 2.735e-07 | 3.978e-05 |
33 | POSITIVE REGULATION OF CELL DEVELOPMENT | 30 | 472 | 2.897e-07 | 4.085e-05 |
34 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 49 | 1021 | 3.566e-07 | 4.88e-05 |
35 | NEURON PROJECTION MORPHOGENESIS | 27 | 402 | 3.934e-07 | 5.085e-05 |
36 | CELL PROJECTION ORGANIZATION | 45 | 902 | 3.845e-07 | 5.085e-05 |
37 | SKELETAL SYSTEM DEVELOPMENT | 29 | 455 | 4.333e-07 | 5.305e-05 |
38 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 53 | 1152 | 4.266e-07 | 5.305e-05 |
39 | MUSCLE STRUCTURE DEVELOPMENT | 28 | 432 | 4.914e-07 | 5.716e-05 |
40 | BIOLOGICAL ADHESION | 49 | 1032 | 4.881e-07 | 5.716e-05 |
41 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 28 | 437 | 6.186e-07 | 7.02e-05 |
42 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 15 | 144 | 7.965e-07 | 8.824e-05 |
43 | HEAD MORPHOGENESIS | 8 | 36 | 9.879e-07 | 0.0001069 |
44 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 59 | 1381 | 1.038e-06 | 0.0001098 |
45 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 22 | 303 | 1.323e-06 | 0.0001368 |
46 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 41 | 823 | 1.353e-06 | 0.0001368 |
47 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 71 | 1805 | 1.552e-06 | 0.0001536 |
48 | RESPONSE TO HORMONE | 43 | 893 | 1.791e-06 | 0.0001703 |
49 | DEVELOPMENTAL GROWTH | 23 | 333 | 1.793e-06 | 0.0001703 |
50 | ORGAN MORPHOGENESIS | 41 | 841 | 2.324e-06 | 0.0002162 |
51 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 33 | 609 | 2.612e-06 | 0.0002383 |
52 | REGULATION OF CELL PROJECTION ORGANIZATION | 31 | 558 | 3.186e-06 | 0.0002851 |
53 | ACTIN FILAMENT BASED PROCESS | 27 | 450 | 3.41e-06 | 0.0002994 |
54 | OVULATION CYCLE PROCESS | 11 | 88 | 4.013e-06 | 0.0003458 |
55 | SYNAPSE ORGANIZATION | 14 | 145 | 4.567e-06 | 0.0003864 |
56 | CENTRAL NERVOUS SYSTEM NEURON DIFFERENTIATION | 15 | 166 | 4.773e-06 | 0.0003966 |
57 | BODY MORPHOGENESIS | 8 | 44 | 4.951e-06 | 0.0004042 |
58 | CYTOSKELETON ORGANIZATION | 40 | 838 | 5.154e-06 | 0.0004134 |
59 | POSITIVE REGULATION OF GENE EXPRESSION | 67 | 1733 | 5.731e-06 | 0.0004519 |
60 | GROWTH | 25 | 410 | 5.949e-06 | 0.0004614 |
61 | VASCULATURE DEVELOPMENT | 27 | 469 | 7.294e-06 | 0.0005564 |
62 | OVULATION CYCLE | 12 | 113 | 8.245e-06 | 0.0006187 |
63 | RESPONSE TO NITROGEN COMPOUND | 40 | 859 | 9.238e-06 | 0.0006823 |
64 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 28 | 505 | 9.949e-06 | 0.0007233 |
65 | CELL GROWTH | 13 | 135 | 1.027e-05 | 0.0007351 |
66 | GLOMERULUS DEVELOPMENT | 8 | 49 | 1.143e-05 | 0.0007938 |
67 | REGULATION OF SMOOTH MUSCLE CELL MIGRATION | 8 | 49 | 1.143e-05 | 0.0007938 |
68 | RHYTHMIC PROCESS | 20 | 298 | 1.288e-05 | 0.000881 |
69 | FACE DEVELOPMENT | 8 | 50 | 1.335e-05 | 0.0008999 |
70 | RESPONSE TO PEPTIDE | 24 | 404 | 1.406e-05 | 0.0009326 |
71 | INTRACELLULAR SIGNAL TRANSDUCTION | 61 | 1572 | 1.423e-05 | 0.0009326 |
72 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 44 | 1004 | 1.478e-05 | 0.0009422 |
73 | BEHAVIOR | 28 | 516 | 1.476e-05 | 0.0009422 |
74 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 52 | 1275 | 1.752e-05 | 0.001101 |
75 | COLLAGEN FIBRIL ORGANIZATION | 7 | 38 | 1.79e-05 | 0.00111 |
76 | DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS | 11 | 104 | 2.034e-05 | 0.001245 |
77 | CELLULAR RESPONSE TO AMINO ACID STIMULUS | 8 | 53 | 2.078e-05 | 0.001256 |
78 | RESPONSE TO OXYGEN LEVELS | 20 | 311 | 2.386e-05 | 0.001423 |
79 | ENSHEATHMENT OF NEURONS | 10 | 91 | 3.46e-05 | 0.002012 |
80 | AXON ENSHEATHMENT | 10 | 91 | 3.46e-05 | 0.002012 |
81 | TISSUE DEVELOPMENT | 58 | 1518 | 3.679e-05 | 0.002113 |
82 | CELL PART MORPHOGENESIS | 31 | 633 | 3.785e-05 | 0.002147 |
83 | CELLULAR RESPONSE TO ACID CHEMICAL | 14 | 175 | 3.892e-05 | 0.002182 |
84 | LOCOMOTION | 46 | 1114 | 4.104e-05 | 0.002274 |
85 | REGULATION OF METAL ION TRANSPORT | 20 | 325 | 4.449e-05 | 0.002436 |
86 | CELLULAR RESPONSE TO HORMONE STIMULUS | 28 | 552 | 4.904e-05 | 0.002512 |
87 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 53 | 1360 | 4.913e-05 | 0.002512 |
88 | SENSORY ORGAN DEVELOPMENT | 26 | 493 | 4.803e-05 | 0.002512 |
89 | MODULATION OF SYNAPTIC TRANSMISSION | 19 | 301 | 4.887e-05 | 0.002512 |
90 | REGULATION OF CELL PROLIFERATION | 57 | 1496 | 4.669e-05 | 0.002512 |
91 | REGULATION OF CELL MORPHOGENESIS | 28 | 552 | 4.904e-05 | 0.002512 |
92 | TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 10 | 95 | 5.027e-05 | 0.002542 |
93 | NEGATIVE REGULATION OF CELL DEVELOPMENT | 19 | 303 | 5.343e-05 | 0.002617 |
94 | MUSCLE ORGAN DEVELOPMENT | 18 | 277 | 5.288e-05 | 0.002617 |
95 | REGULATION OF NEURON DEATH | 17 | 252 | 5.343e-05 | 0.002617 |
96 | RESPONSE TO COCAINE | 7 | 46 | 6.511e-05 | 0.003156 |
97 | POSITIVE REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 8 | 62 | 6.658e-05 | 0.003194 |
98 | RESPONSE TO WOUNDING | 28 | 563 | 6.897e-05 | 0.003275 |
99 | POSITIVE REGULATION OF NUCLEAR TRANSCRIBED MRNA POLY A TAIL SHORTENING | 4 | 11 | 7.048e-05 | 0.00328 |
100 | REGULATION OF NUCLEAR TRANSCRIBED MRNA POLY A TAIL SHORTENING | 4 | 11 | 7.048e-05 | 0.00328 |
101 | REGULATION OF CALCIUM ION TRANSPORT | 15 | 209 | 7.278e-05 | 0.003353 |
102 | REGULATION OF MUSCLE ADAPTATION | 8 | 63 | 7.48e-05 | 0.003412 |
103 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 32 | 689 | 7.772e-05 | 0.003511 |
104 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 66 | 1848 | 8.037e-05 | 0.003596 |
105 | MUSCLE CELL DIFFERENTIATION | 16 | 237 | 8.733e-05 | 0.00387 |
106 | PLATELET DERIVED GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 6 | 34 | 9.299e-05 | 0.004082 |
107 | RESPONSE TO ESTRADIOL | 12 | 146 | 0.0001063 | 0.00462 |
108 | DEVELOPMENTAL MATURATION | 14 | 193 | 0.0001123 | 0.004839 |
109 | CONNECTIVE TISSUE DEVELOPMENT | 14 | 194 | 0.0001187 | 0.005065 |
110 | NEGATIVE REGULATION OF CELL PROLIFERATION | 30 | 643 | 0.0001199 | 0.005074 |
111 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 56 | 1517 | 0.0001268 | 0.005223 |
112 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 34 | 771 | 0.0001267 | 0.005223 |
113 | REGULATION OF TRANSPORT | 64 | 1804 | 0.0001264 | 0.005223 |
114 | SINGLE ORGANISM BEHAVIOR | 21 | 384 | 0.0001545 | 0.006202 |
115 | WOUND HEALING | 24 | 470 | 0.0001524 | 0.006202 |
116 | GLIOGENESIS | 13 | 175 | 0.0001546 | 0.006202 |
117 | PROTEIN PHOSPHORYLATION | 39 | 944 | 0.0001596 | 0.006343 |
118 | REGULATION OF ION TRANSPORT | 28 | 592 | 0.0001608 | 0.006343 |
119 | RESPONSE TO GROWTH FACTOR | 24 | 475 | 0.0001785 | 0.006979 |
120 | REGULATION OF HOMEOSTATIC PROCESS | 23 | 447 | 0.0001865 | 0.007232 |
121 | REGULATION OF SYSTEM PROCESS | 25 | 507 | 0.0001913 | 0.007357 |
122 | BONE DEVELOPMENT | 12 | 156 | 0.0001988 | 0.007521 |
123 | NEGATIVE REGULATION OF CELL COMMUNICATION | 46 | 1192 | 0.0001988 | 0.007521 |
124 | RESPONSE TO AMINO ACID | 10 | 112 | 0.0002014 | 0.007557 |
125 | REGULATION OF PHOSPHOLIPASE C ACTIVITY | 6 | 39 | 0.0002054 | 0.007584 |
126 | ASTROCYTE DIFFERENTIATION | 6 | 39 | 0.0002054 | 0.007584 |
127 | BLOOD VESSEL MORPHOGENESIS | 20 | 364 | 0.0002072 | 0.007592 |
128 | RESPONSE TO ABIOTIC STIMULUS | 41 | 1024 | 0.0002098 | 0.007627 |
129 | NEURON PROJECTION GUIDANCE | 14 | 205 | 0.0002114 | 0.007627 |
130 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 19 | 337 | 0.0002144 | 0.007673 |
131 | REGULATION OF SYNAPSE STRUCTURE OR ACTIVITY | 15 | 232 | 0.000231 | 0.008206 |
132 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 6 | 40 | 0.0002371 | 0.008233 |
133 | NEGATIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 6 | 40 | 0.0002371 | 0.008233 |
134 | GLIAL CELL DIFFERENTIATION | 11 | 136 | 0.0002353 | 0.008233 |
135 | HINDBRAIN DEVELOPMENT | 11 | 137 | 0.0002508 | 0.008646 |
136 | REGULATION OF RAS PROTEIN SIGNAL TRANSDUCTION | 13 | 184 | 0.0002537 | 0.008678 |
137 | POSITIVE REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY | 4 | 15 | 0.0002716 | 0.009093 |
138 | FEMALE SEX DIFFERENTIATION | 10 | 116 | 0.0002683 | 0.009093 |
139 | REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY | 4 | 15 | 0.0002716 | 0.009093 |
140 | POSITIVE REGULATION OF TRANSPORT | 38 | 936 | 0.0002737 | 0.009096 |
141 | NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 16 | 262 | 0.0002759 | 0.009106 |
142 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 32 | 740 | 0.0002826 | 0.009197 |
143 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 12 | 162 | 0.0002821 | 0.009197 |
144 | REGULATION OF SYNAPTIC PLASTICITY | 11 | 140 | 0.0003027 | 0.009782 |
145 | RESPONSE TO ACID CHEMICAL | 18 | 319 | 0.000309 | 0.009917 |
146 | GLAND MORPHOGENESIS | 9 | 97 | 0.0003124 | 0.009956 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | EXTRACELLULAR MATRIX STRUCTURAL CONSTITUENT | 16 | 76 | 8.802e-12 | 8.177e-09 |
2 | PLATELET DERIVED GROWTH FACTOR BINDING | 7 | 11 | 7.872e-10 | 3.656e-07 |
3 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 53 | 1199 | 1.433e-06 | 0.0004439 |
4 | GROWTH FACTOR BINDING | 13 | 123 | 3.669e-06 | 0.0008521 |
5 | CYTOSKELETAL PROTEIN BINDING | 39 | 819 | 7.18e-06 | 0.0009188 |
6 | ACTIN BINDING | 24 | 393 | 8.901e-06 | 0.0009188 |
7 | METALLOENDOPEPTIDASE ACTIVITY | 12 | 113 | 8.245e-06 | 0.0009188 |
8 | ZINC ION BINDING | 50 | 1155 | 5.22e-06 | 0.0009188 |
9 | MACROMOLECULAR COMPLEX BINDING | 57 | 1399 | 6.843e-06 | 0.0009188 |
10 | PROTEIN COMPLEX BINDING | 42 | 935 | 1.305e-05 | 0.001212 |
11 | ENZYME BINDING | 65 | 1737 | 2.258e-05 | 0.001907 |
12 | TRANSITION METAL ION BINDING | 55 | 1400 | 2.806e-05 | 0.002172 |
13 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 31 | 629 | 3.359e-05 | 0.0024 |
14 | TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING | 29 | 588 | 5.944e-05 | 0.003944 |
15 | CELL ADHESION MOLECULE BINDING | 14 | 186 | 7.565e-05 | 0.004685 |
16 | INTEGRIN BINDING | 10 | 105 | 0.0001178 | 0.006439 |
17 | RECEPTOR BINDING | 55 | 1476 | 0.000115 | 0.006439 |
18 | CALMODULIN BINDING | 13 | 179 | 0.0001935 | 0.009987 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | EXTRACELLULAR MATRIX COMPONENT | 27 | 125 | 2.697e-19 | 1.575e-16 |
2 | EXTRACELLULAR MATRIX | 45 | 426 | 3.542e-18 | 1.034e-15 |
3 | PROTEINACEOUS EXTRACELLULAR MATRIX | 41 | 356 | 5.384e-18 | 1.048e-15 |
4 | BASEMENT MEMBRANE | 19 | 93 | 1.717e-13 | 2.508e-11 |
5 | COMPLEX OF COLLAGEN TRIMERS | 11 | 23 | 6.223e-13 | 7.269e-11 |
6 | NEURON PART | 62 | 1265 | 3.735e-09 | 3.636e-07 |
7 | SOMATODENDRITIC COMPARTMENT | 40 | 650 | 7.012e-09 | 5.85e-07 |
8 | COLLAGEN TRIMER | 14 | 88 | 8.531e-09 | 6.227e-07 |
9 | NEURON PROJECTION | 50 | 942 | 1.163e-08 | 7.544e-07 |
10 | ENDOPLASMIC RETICULUM LUMEN | 19 | 201 | 1.295e-07 | 7.563e-06 |
11 | CELL JUNCTION | 54 | 1151 | 1.766e-07 | 9.376e-06 |
12 | SYNAPSE | 40 | 754 | 3.774e-07 | 1.837e-05 |
13 | DENDRITE | 27 | 451 | 3.554e-06 | 0.0001596 |
14 | T TUBULE | 8 | 45 | 5.905e-06 | 0.0002463 |
15 | CELL BODY | 28 | 494 | 6.611e-06 | 0.0002574 |
16 | AXON | 24 | 418 | 2.45e-05 | 0.0008944 |
17 | CELL PROJECTION | 66 | 1786 | 2.862e-05 | 0.0009833 |
18 | SYNAPSE PART | 30 | 610 | 4.674e-05 | 0.001517 |
19 | BANDED COLLAGEN FIBRIL | 4 | 12 | 0.0001039 | 0.003193 |
20 | SARCOLEMMA | 11 | 125 | 0.0001114 | 0.003254 |
21 | ACTIN CYTOSKELETON | 23 | 444 | 0.0001692 | 0.004705 |
22 | FIBRIL | 4 | 14 | 0.0002027 | 0.005382 |
23 | PLATELET ALPHA GRANULE | 8 | 75 | 0.0002583 | 0.00656 |
24 | POSTSYNAPSE | 20 | 378 | 0.0003384 | 0.008234 |
25 | HISTONE DEACETYLASE COMPLEX | 7 | 61 | 0.0003985 | 0.00931 |
26 | ACTOMYOSIN | 7 | 62 | 0.0004408 | 0.009901 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | Focal_adhesion_hsa04510 | 23 | 199 | 1.163e-10 | 6.046e-09 | |
2 | Ras_signaling_pathway_hsa04014 | 20 | 232 | 2.735e-07 | 6.58e-06 | |
3 | PI3K_Akt_signaling_pathway_hsa04151 | 25 | 352 | 3.796e-07 | 6.58e-06 | |
4 | ECM_receptor_interaction_hsa04512 | 11 | 82 | 1.979e-06 | 2.572e-05 | |
5 | FoxO_signaling_pathway_hsa04068 | 13 | 132 | 8.031e-06 | 8.352e-05 | |
6 | ErbB_signaling_pathway_hsa04012 | 9 | 85 | 0.0001138 | 0.0009859 | |
7 | cAMP_signaling_pathway_hsa04024 | 14 | 198 | 0.0001472 | 0.001093 | |
8 | AMPK_signaling_pathway_hsa04152 | 10 | 121 | 0.0003773 | 0.002452 | |
9 | Calcium_signaling_pathway_hsa04020 | 12 | 182 | 0.0008035 | 0.004642 | |
10 | Cellular_senescence_hsa04218 | 11 | 160 | 0.000933 | 0.004723 | |
11 | Apelin_signaling_pathway_hsa04371 | 10 | 137 | 0.0009991 | 0.004723 | |
12 | Phospholipase_D_signaling_pathway_hsa04072 | 10 | 146 | 0.001617 | 0.006468 | |
13 | Wnt_signaling_pathway_hsa04310 | 10 | 146 | 0.001617 | 0.006468 | |
14 | Regulation_of_actin_cytoskeleton_hsa04810 | 12 | 208 | 0.0025 | 0.009287 | |
15 | Gap_junction_hsa04540 | 7 | 88 | 0.003476 | 0.01205 | |
16 | Rap1_signaling_pathway_hsa04015 | 11 | 206 | 0.006604 | 0.02139 | |
17 | HIF_1_signaling_pathway_hsa04066 | 7 | 100 | 0.006994 | 0.02139 | |
18 | Hippo_signaling_pathway_hsa04390 | 9 | 154 | 0.007672 | 0.02216 | |
19 | Jak_STAT_signaling_pathway_hsa04630 | 9 | 162 | 0.01051 | 0.02875 | |
20 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 8 | 139 | 0.01267 | 0.03294 | |
21 | MAPK_signaling_pathway_hsa04010 | 13 | 295 | 0.01535 | 0.038 | |
22 | Oocyte_meiosis_hsa04114 | 7 | 124 | 0.02101 | 0.04965 | |
23 | Autophagy_animal_hsa04140 | 7 | 128 | 0.02449 | 0.05537 | |
24 | Hippo_signaling_pathway_multiple_species_hsa04392 | 3 | 29 | 0.02605 | 0.05644 | |
25 | cGMP_PKG_signaling_pathway_hsa04022 | 8 | 163 | 0.02972 | 0.06181 | |
26 | Cell_cycle_hsa04110 | 6 | 124 | 0.05888 | 0.1178 | |
27 | TGF_beta_signaling_pathway_hsa04350 | 4 | 84 | 0.1175 | 0.2253 | |
28 | mTOR_signaling_pathway_hsa04150 | 6 | 151 | 0.1213 | 0.2253 | |
29 | Cytokine_cytokine_receptor_interaction_hsa04060 | 9 | 270 | 0.1498 | 0.2686 | |
30 | Apoptosis_multiple_species_hsa04215 | 2 | 33 | 0.1666 | 0.2888 | |
31 | Mitophagy_animal_hsa04137 | 3 | 65 | 0.176 | 0.291 | |
32 | Tight_junction_hsa04530 | 6 | 170 | 0.1791 | 0.291 | |
33 | Adherens_junction_hsa04520 | 3 | 72 | 0.2158 | 0.3367 | |
34 | TNF_signaling_pathway_hsa04668 | 4 | 108 | 0.2201 | 0.3367 | |
35 | Phagosome_hsa04145 | 5 | 152 | 0.2507 | 0.3725 | |
36 | Sphingolipid_signaling_pathway_hsa04071 | 4 | 118 | 0.2684 | 0.3876 | |
37 | Hedgehog_signaling_pathway_hsa04340 | 2 | 47 | 0.2813 | 0.3953 | |
38 | Apoptosis_hsa04210 | 4 | 138 | 0.3688 | 0.4928 | |
39 | Phosphatidylinositol_signaling_system_hsa04070 | 3 | 99 | 0.3787 | 0.4928 | |
40 | VEGF_signaling_pathway_hsa04370 | 2 | 59 | 0.3791 | 0.4928 | |
41 | Cell_adhesion_molecules_.CAMs._hsa04514 | 4 | 145 | 0.404 | 0.5124 | |
42 | p53_signaling_pathway_hsa04115 | 2 | 68 | 0.4487 | 0.5556 | |
43 | Endocytosis_hsa04144 | 6 | 244 | 0.4601 | 0.5564 | |
44 | Necroptosis_hsa04217 | 4 | 164 | 0.4972 | 0.5876 | |
45 | Neuroactive_ligand_receptor_interaction_hsa04080 | 6 | 278 | 0.587 | 0.6783 | |
46 | NF_kappa_B_signaling_pathway_hsa04064 | 2 | 95 | 0.6278 | 0.7097 |